Gastric Cancer
Gastric Cancer
Advertisement
Benjamin Weinberg, MD, FACPColorectal Cancer | June 30, 2025
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Nataliya Uboha, MD, PhDGastric Cancer | June 26, 2025
The panel concludes with a discussion on treatment strategies for metastatic esophageal squamous cell carcinoma.
Nataliya Uboha, MD, PhDGastric Cancer | June 26, 2025
The panel shifts focus to the 1L treatment of metastatic gastroesophageal cancers, exploring biomarker testing strategies.
Nataliya Uboha, MD, PhDGastric Cancer | June 26, 2025
The panel delves into the implications of recent data on IO in the perioperative, adjuvant treatment of upper GI cancers.
Nataliya Uboha, MD, PhDGastric Cancer | June 26, 2025
The panel takes a deep dive into the evolving role of IO in resectable GE cancer, with a focus on the results of MATTERHORN.
Nataliya Uboha, MD, PhDGastric Cancer | June 26, 2025
The panel launches into a discussion of practice-changing data, focusing on MATTERHORN and its impact on disease management.
Yelena Janjigian, MDGastric Cancer | June 16, 2025
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Filippo Pietrantonio, MDGastric Cancer | June 10, 2025
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Lauren Dembeck, PhDEsophageal Cancer | June 9, 2025
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Zev Wainberg, MD, MScGastric Cancer | June 6, 2025
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Jessica Nye, PhDEsophageal Cancer | June 6, 2025
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Jessica GangaGastric Cancer | May 23, 2025
Circulating tumor DNA burden in patients with gastric cancer may aid oncologists in determining treatment options.
Samuel Cytryn, MDGastric Cancer | May 9, 2025
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Yelena Janjigian, MDGastric Cancer | April 15, 2025
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Emily MenendezGastric Cancer | March 26, 2025
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Emily MenendezGastric Cancer | March 25, 2025
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
Emily MenendezEsophageal Cancer | March 12, 2025
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Samuel Cytryn, MDGastric Cancer | March 19, 2025
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Laurence Albiges, MD, PhDGastric Cancer | March 19, 2025
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
Samuel Cytryn, MDGastric Cancer | March 19, 2025
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Advertisement